Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 213Lung Neoplasms 79Triple Negative Breast Neoplasms 67Breast Neoplasms 67Ovarian Neoplasms 56Squamous Cell Carcinoma of Head and Neck 49Small Cell Lung Carcinoma 47Fallopian Tube Neoplasms 37Endometrial Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 28Neoplasm Metastasis 28Head and Neck Neoplasms 24Prostatic Neoplasms 20Carcinoma 19Esophageal Neoplasms 18Urinary Bladder Neoplasms 16Colorectal Neoplasms 16Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Squamous Cell 14Esophageal Squamous Cell Carcinoma 13Brain Neoplasms 12Stomach Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Mouth Neoplasms 9Laryngeal Neoplasms 9Carcinoma, Ovarian Epithelial 9

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Carboplatin × 1 year × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
15 enrolled 17 charts
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡